These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 24148854)

  • 1. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.
    Sanders LH; Laganière J; Cooper O; Mak SK; Vu BJ; Huang YA; Paschon DE; Vangipuram M; Sundararajan R; Urnov FD; Langston JW; Gregory PD; Zhang HS; Greenamyre JT; Isacson O; Schüle B
    Neurobiol Dis; 2014 Feb; 62():381-6. PubMed ID: 24148854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation.
    Chang KH; Huang CY; Ou-Yang CH; Ho CH; Lin HY; Hsu CL; Chen YT; Chou YC; Chen YJ; Chen Y; Lin JL; Wang JK; Lin PW; Lin YR; Lin MH; Tseng CK; Lin CH
    Stem Cell Res Ther; 2021 Sep; 12(1):508. PubMed ID: 34551822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.
    Liu GH; Qu J; Suzuki K; Nivet E; Li M; Montserrat N; Yi F; Xu X; Ruiz S; Zhang W; Wagner U; Kim A; Ren B; Li Y; Goebl A; Kim J; Soligalla RD; Dubova I; Thompson J; Yates J; Esteban CR; Sancho-Martinez I; Izpisua Belmonte JC
    Nature; 2012 Nov; 491(7425):603-7. PubMed ID: 23075850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation.
    Schwab AJ; Ebert AD
    Stem Cell Reports; 2015 Dec; 5(6):1039-1052. PubMed ID: 26651604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-cell autonomous mechanism of Parkinson's disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis.
    Kim J; Daadi MM
    Brain Res; 2019 Nov; 1722():146342. PubMed ID: 31330122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
    Su YC; Qi X
    Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).
    Beylina A; Langston RG; Rosen D; Reed X; Cookson MR
    Stem Cell Res; 2021 May; 53():102354. PubMed ID: 34087985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation.
    Bono F; Mutti V; Devoto P; Bolognin S; Schwamborn JC; Missale C; Fiorentini C
    Neurobiol Aging; 2021 Mar; 99():65-78. PubMed ID: 33422895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and characterization of induced pluripotent stem cells from a Parkinson's disease patient carrying the digenic LRRK2 p.G2019S and GBA1 p.N409S mutations.
    Oleksy C; Massart F; Goldwurm S; Arado A; Arena G; Boussaad I; Krüger R
    Stem Cell Res; 2023 Oct; 72():103212. PubMed ID: 37832355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.
    Reinhardt P; Schmid B; Burbulla LF; Schöndorf DC; Wagner L; Glatza M; Höing S; Hargus G; Heck SA; Dhingra A; Wu G; Müller S; Brockmann K; Kluba T; Maisel M; Krüger R; Berg D; Tsytsyura Y; Thiel CS; Psathaki OE; Klingauf J; Kuhlmann T; Klewin M; Müller H; Gasser T; Schöler HR; Sterneckert J
    Cell Stem Cell; 2013 Mar; 12(3):354-67. PubMed ID: 23472874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.
    Schwab AJ; Sison SL; Meade MR; Broniowska KA; Corbett JA; Ebert AD
    Stem Cell Reports; 2017 Dec; 9(6):1839-1852. PubMed ID: 29129681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human iPSC-derived microglia carrying the LRRK2-G2019S mutation show a Parkinson's disease related transcriptional profile and function.
    Ohtonen S; Giudice L; Jäntti H; Fazaludeen MF; Shakirzyanova A; Gómez-Budia M; Välimäki NN; Niskanen J; Korvenlaita N; Fagerlund I; Koistinaho J; Amiry-Moghaddam M; Savchenko E; Roybon L; Lehtonen Š; Korhonen P; Malm T
    Sci Rep; 2023 Dec; 13(1):22118. PubMed ID: 38092815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does uncoupling protein 2 expression qualify as marker of disease status in LRRK2-associated Parkinson's disease?
    Grünewald A; Arns B; Meier B; Brockmann K; Tadic V; Klein C
    Antioxid Redox Signal; 2014 May; 20(13):1955-60. PubMed ID: 24251413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania.
    De Rosa A; De Michele G; Guacci A; Carbone R; Lieto M; Peluso S; Picillo M; Barone P; Salemi F; Laiso A; Saccà F; Tessitore A; Pellecchia MT; Bonifati V; Criscuolo C
    J Parkinsons Dis; 2014; 4(1):123-8. PubMed ID: 24496098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.
    Momcilovic O; Sivapatham R; Oron TR; Meyer M; Mooney S; Rao MS; Zeng X
    PLoS One; 2016; 11(5):e0154890. PubMed ID: 27191603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.
    Gonzalez-Hunt CP; Thacker EA; Toste CM; Boularand S; Deprets S; Dubois L; Sanders LH
    Sci Rep; 2020 Oct; 10(1):17293. PubMed ID: 33057100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
    Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
    Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.